QIAGEN has launched customizable QIAact target enrichment panels for analysis of more than 13 hereditary disease groups. The solutions integrate QIAGEN’s QCI analysis and interpretation solutions, in particular also QIAGEN’s  HGMD Human Gene Mutation Database, the leading genomic knowledge base on hereditary diseases, with integrated bioinformatics analysis and interpretation software to deliver clear, actionable reports.

This integrated solution will allow for the analysis of specific sets of genetic hereditary disorders of interest, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, universal carrier screening and various other hereditary conditions.

“Genetic laboratories are eager to gain deeper insights into a range of hereditary diseases by using the power of NGS technology, but have been held back by the lack of complete workflows and powerful bioinformatics solutions. We are pleased to offer the first complete Sample to Insight solution for analysis of hereditary diseases. Our solution, anchored by the GeneReader NGS System, provides the complete solution that labs need to efficiently and reliably perform genetic analysis,” said Peer M. Schatz, Chief Executive Officer of QIAGEN.

The expansion of GeneReader for use in analysis of hereditary diseases broadens the system’s pre-designed QIAact panel menu beyond the initial focus on gene panels for oncology, and will further support placements of QIAGEN’s end-to-end solution in labs worldwide. In addition, QIAGEN offers a customization service, which is experiencing rapid and broad adoption and allows an unlimited assay menu by tailoring panels to customer’s specifications.

QIAGEN’s QCI is the leading integrated solution for NGS analysis and interpretation in clinical settings. QCI includes the HGMD knowledge base is a unique resource containing comprehensive data on inherited disease mutations for genetic and genomic research. Assembled by highly qualified subject-matter experts, HGMD offers research and clinical labs a comprehensive and easy-to-use database to connect disparate genetic and clinical findings and identify inheritance patterns.  

About the GeneReader system

The GeneReader NGS System provides the first true Sample to Insight NGS workflow for laboratories worldwide to take advantage of the power of NGS technology. The system’s integrated bioinformatics for analysis and interpretation of NGS data, as well as a family of gene panels under the GeneRead QIAact brand, enable laboratories to identify gene variations linked to diseases and gain actionable molecular insights. QIAGEN continues to add content for GeneReader, with a pipeline of potential future tests in areas such as oncology, prenatal testing, infectious disease genotyping, and customized panels for specific needs. Integrated bioinformatics provide streamlined, cloud-based analysis and interpretation. The current version of the GeneReader NGS System is available in the United States for research use only (RUO). For more information please visit www.genereaderngs.com. #betterthanabox

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers‘ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors‘ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).